CFDE Data Portal | Search LNCOC1

	Label	Description
	LNCOC1 Gene (Entity type)	ENSG00000253741 - lncRNA associated with ovarian cancer 1
	GSE213588 trametinib NF1 8 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 6 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE236896 GSE237665 DNMT EZH2 inhibition 1 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE157109 TRIM8 knockdown MCF-7 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE142357 HDAC3 inhibition 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 3 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 3 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE130437 palbociclib 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

LNCOC1

ENSG00000253741 - lncRNA associated with ovarian cancer 1

GSE213588 trametinib NF1 8 v 11 human up

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 6 v 7 human dn

A Gene Set from LINCS

GSE236896 GSE237665 DNMT EZH2 inhibition 1 v 5 human dn

A Gene Set from LINCS

GSE157109 TRIM8 knockdown MCF-7 0 v 1 human dn

A Gene Set from LINCS

GSE142357 HDAC3 inhibition 1 v 3 human up

A Gene Set from LINCS

GSE261563 CX-5461 3 v 8 human up

A Gene Set from LINCS

GSE216043 cisplatin 3 v 4 human up

A Gene Set from LINCS

GSE130437 palbociclib 2 v 1 human dn

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.